Insight2023-10-31T14:10:05+00:00
Loading...

Latest news and thought leadership

All the latest from Deallus pharmaceutical and life science industry experts

National Healthcare Security Administration (NHSA) protocols

November 2nd, 2023|Categories: News|Tags: |

On 4 July 2023, the National Healthcare Security Administration (NHSA) published the drafted 'Protocol for Renewal of NRDL Listed Drugs’ and ‘Negotiation Rules for Non-Exclusive Drug’. The two protocols aim to streamline the negotiation process for NRDL listed drugs and those with generic versions and are eligible for NRDL listing.

China Pharma Market Access (CPMA)

September 13th, 2023|Categories: News, White Paper|Tags: |

Since the establishment of the China National Medical Insurance Bureau in 2018, the goal has been to strengthen public health and medical service levels, achieve maximum utilisation of the national medical insurance fund, and to enhance the strategic purchasing capability of medical insurance funds. Significant tools in achieving this are the National Reimbursement Drug List (NRDL) and drug Volume Based Procurement (VBP), which have opened a new chapter in China’s medical reform. Meanwhile, the new drug registration process is improved, simplified, and accelerated.

Register your email address to be alerted to our latest news

    Go to Top